Tactile Systems Technology, Inc. (TCMD)
| Market Cap | 512.93M +57.2% |
| Revenue (ttm) | 343.52M +17.2% |
| Net Income | 20.30M +25.3% |
| EPS | 0.89 +34.2% |
| Shares Out | 22.56M |
| PE Ratio | 25.67 |
| Forward PE | 18.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 331,463 |
| Open | 22.77 |
| Previous Close | 23.04 |
| Day's Range | 22.51 - 23.14 |
| 52-Week Range | 9.34 - 37.77 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 37.50 (+64.91%) |
| Earnings Date | May 4, 2026 |
About TCMD
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic comp... [Read more]
Financial Performance
In 2025, TCMD's revenue was $329.52 million, an increase of 12.47% compared to the previous year's $292.98 million. Earnings were $19.09 million, an increase of 12.54%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TCMD stock is "Strong Buy." The 12-month stock price target is $37.5, which is an increase of 64.91% from the latest price.
News
Tactile Systems upgraded to Buy from Neutral at B. Riley
B. Riley analyst Anderson Schock upgraded Tactile Systems (TCMD) to Buy from Neutral with a price target of $36, up from $32.
Tactile Systems upgraded to Buy from Neutral at B. Riley
B. Riley upgraded Tactile Systems (TCMD) to Buy from Neutral with a price target of $36, up from $32. Tactile Systems reported a top and bottom line beat for Q1,…
Tactile Systems price target raised to $40 from $38 at BTIG
BTIG raised the firm’s price target on Tactile Systems (TCMD) to $40 from $38 and keeps a Buy rating on the shares. The firm is positive on the company’s earnings…
Tactile Systems Technology Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 23% year-over-year to $75.3 million, with strong gains in both lymphedema and airway clearance segments. Gross margin expanded to 76.5%, and adjusted EBITDA improved to $3.7 million. Full-year guidance was raised, reflecting confidence in commercial execution and the LymphaTech acquisition.
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chron...
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...
Tactile Systems appoints Andrea Pearson to Board of Directors
Tactile Systems (TCMD) Technology announced the appointment of Andrea Pearson to the Company’s Board of Directors and as a member of the Compliance & Reimbursement and Nominating & Corporate Governanc...
Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chr...
Tactile Systems price target raised to $40 from $32 at Lake Street
Lake Street analyst Ben Haynor raised the firm’s price target on Tactile Systems (TCMD) to $40 from $32 and keeps a Buy rating on the shares. Tactile posted “massive upside”…
Tactile Systems price target raised to $32 from $16 at B. Riley
B. Riley raised the firm’s price target on Tactile Systems (TCMD) to $32 from $16 and keeps a Neutral rating on the shares. While the Q4 results and 2025 execution…
Tactile Systems price target raised to $38 from $36 at BTIG
BTIG raised the firm’s price target on Tactile Systems (TCMD) to $38 from $36 and keeps a Buy rating on the shares after its Q4 earnings beat and above-consensus guide.
Tactile Systems price target raised to $42 from $35 at Piper Sandler
Piper Sandler raised the firm’s price target on Tactile Systems (TCMD) to $42 from $35 and keeps an Overweight rating on the shares. The firm notes the company posted strong…
Tactile Systems Technology Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 12% revenue growth, margin expansion, and record Q4 performance. 2026 guidance anticipates 8%-11% growth, factoring in a short-term Medicare prior authorization headwind. Acquisition of LymphaTech and new product launches support long-term growth.
Tactile Systems LymphaTech for $6.8M upfront
Tactile Systems (TCMD) announced that it has acquired LymphaTech for an upfront cash payment at closing of $6.8M, plus potential additional consideration that is contingent upon the achievement of fut...
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
LymphaTech's 3D Platform and Digital Capabilities to Improve Disease Identification, Accelerate Therapy Adoption, and Support Next-Generation Lymphatic Therapies LymphaTech's 3D Platform and Digital C...
Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Piper Sandler upgrades Tactile Systems to Overweight on favorable risk-reward
As previously reported, Piper Sandler analyst Adam Maeder upgraded Tactile Systems (TCMD) to Overweight from Neutral with a price target of $35, up from $20. The firm notes the lymphedema…
Tactile Systems upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Adam Maeder upgraded Tactile Systems (TCMD) to Overweight from Neutral with a price target of $35, up from $20.
Tactile Systems Technology Transcript: Piper Sandler 37th Annual Healthcare Conference
Strong Q3 results and market leadership in both lymphedema and airway clearance were driven by strategic investments, salesforce transformation, and product innovation. Regulatory clarity and new clinical data are expected to further boost growth, with double-digit expansion anticipated in both core segments.
Tactile Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chro...
Tactile Systems price target raised to $20 from $14 at Piper Sandler
Piper Sandler raised the firm’s price target on Tactile Systems (TCMD) to $20 from $14 and keeps a Neutral rating on the shares. The firm notes the company posted Q3…
Tactile Systems price target raised to $32 from $23.50 at Lake Street
Lake Street raised the firm’s price target on Tactile Systems (TCMD) to $32 from $23.50 and keeps a Buy rating on the shares after “a massive Q3 outperformance” that included…
Tactile Systems upgraded to Buy from Neutral at BTIG
BTIG upgraded Tactile Systems (TCMD) to Buy from Neutral with a $28 price target The firm views the company’s Q3 results as “very encouraging.” Tactile beat expectations for the second…
Tactile Systems Technology Earnings Call Transcript: Q3 2025
Q3 2025 saw 17% revenue growth, margin expansion, and strong gains in both lymphedema and airway clearance segments. Guidance for 2025 was raised, supported by operational investments, new product launches, and favorable Medicare policy changes.